Should sales growth driven by new products be valued more highly than income wrung out of additional indications? Those who answer yes might be interested to discover that, among big pharma, the top lines of Glaxosmithkline, Pfizer and Novartis are the most reliant on novel projects in 2024.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,